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Abstract: Type 2 diabetes is associated with decreased incretin hormone response to an oral 
  glucose load, and a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secre-
tion. Incretin-based therapies offer a new option for treatment of type 2 diabetes. Saxagliptin, 
a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor specifically designed for extended 
inhibition of the DPP-4 enzyme, causes increased endogenous GLP-1 concentration. In a 
phase 3 clinical trials program of 24 weeks duration, saxagliptin was studied in 6 multicenter, 
multinational, randomized, controlled studies and in combination with 3 of the most commonly 
administered oral antidiabetic drugs: metformin, glyburide and a thiozolidinedione (TZD). 
Saxagliptin provided significant reductions in hemoglobin HbA1c when given with metformin, 
glyburide, a TZD, or as monotherapy. Saxagliptin also reduced fasting plasma glucose and 2-hour 
post-prandial glucose in each of these studies, and was weight and lipid neutral. Saxagliptin was 
well tolerated and had a low risk of hypoglycemia when used as monotherapy.
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Introduction
Type 2 diabetes is a growing epidemic worldwide for which medical treatments 
are still actively sought. The nationwide incidence of diabetes has nearly doubled 
in the last decade. In the United States 17.9 million people have been diagnosed 
with type 2 diabetes, and another 5.7 million remain undiagnosed.1 Three landmark 
prospective, interventional studies – the Diabetes Control and Complications Trial 
(DCCT),2,3 the Kumamoto study,4 and the United Kingdom Prospective Diabetes 
Study (UKPDS)5 – showed significant reductions in the incidence of microvascular 
complications in patients with diabetes who were treated intensively, compared with 
conventional treatment. The DCCT, Kumamoto study, and UKPDS provide the 
accepted evidence that optimal glycemic control reduces the risk of complications. Yet 
glycemic control rates in the US and worldwide are poor and may be on the decline.6 
After adjustment for age, ethnicity, sex, body mass index (BMI), medication use, and 
duration of diabetes, the odds of attaining glycemic control were 21% lower in the 
National Health and Nutrition Examination Survey (NHANES) 1999 to 2000 than 
in NHANES III (1988 to 1994; odds ratio, 0.79).7 Only 37.0% of those surveyed in 
1999–2000 had hemoglobin HbA1c (HbA1c) levels of ,7.0%, a proportion even smaller 
than the 44.3% reported for 1988 to 1994.6 This difference, although not statistically 
significant, shows a trend that must be reversed. 57.1% of patients with diagnosed 
diabetes have an HbA1c at or below the ADA guideline-recommended level of 7%.8
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The failure to achieve adequate glycemic control has led 
to further study of the pathogenesis of the disease and new 
drug discovery. We now understand that insulin demand 
increases in persons with increased caloric consumption, 
decreased physical activity, and increased age. Persons who 
are unable to compensate for increased insulin demand can 
develop prediabetes states, such as impaired glucose toler-
ance (IGT) and impaired fasting glucose (IFG), which can 
then progress to type 2 diabetes.
In patients who develop type 2 diabetes, beta-cell func-
tion appears to decline over time. Postprandial hyperglyce-
mia develops gradually, later followed by a rise in fasting 
plasma glucose (FPG) levels. Hence, IGT and IFG represent 
intermediate steps in the progression to the clinical diagnosis 
of diabetes. Complications, including macrovascular and 
microvascular changes, begin well in advance of the clinical 
diagnosis of type 2 diabetes.
Incretin hormones play an important role in the regu-
lation of blood glucose. Increased understanding of the 
glucoregulatory action of incretin hormones has yielded 
greater insight into the pathophysiology of diabetes and 
has led to the development of new treatments for patients 
with type 2 diabetes. Incretin hormone glucose-dependent 
insulinotropic peptide (GIP) is mainly secreted by the K 
cells in the duodenum and the proximal small intestine and 
glucagon-like peptide-1 (GLP-1) is secreted from the L cells 
of the distal gut. Specifically, it has been demonstrated that 
the endogenous human incretin hormone GLP-1 decreases 
blood glucose by several pathways – via the regulation of 
insulin and glucagon, inhibition of gastric emptying, and 
suppression of appetite, and that the normal physiologic 
response to GLP-1 is impaired in type 2 diabetes.9,10,11 GLP-1 
stimulates insulin secretion in a glucose-dependent manner 
and suppresses glucagon secretion.10 In normal physiol-
ogy, oral ingestion of nutrients stimulates GIP and GLP-1 
secretion, which in turn increases insulin secretion from 
pancreatic beta-cells. Some studies have demonstrated a 
progressive decline in postprandial GLP-1 secretion, where 
individuals with normal glucose tolerance secrete more 
than those with impaired glucose tolerance, and individuals 
with type 2 diabetes demonstrate the greatest impairment 
in GLP-1 secretion.11 The clinical utility of native GLP-1 is 
limited by its short half-life (,2 minutes) due to its rapid 
degradation to inactive metabolites by the enzyme dipeptidyl 
peptidase-4 (DPP-4).10 Because of this limitation, new treat-
ment approach has been developed to inhibit DPP-4 enzyme 
and thereby increase endogenous incretin hormone levels. 
They have shown a beneficial effect on beta-cell function in 
animal studies but there are no clinical trials to date showing 
preservation of beta-cell function.10
The first DPP-4 inhibitor, sitagliptin, was approved by 
the Food and Drug Administration (FDA) in 2006 for use as 
monothearpy or in combination with metformin or thiozoli-
dinediones (TZDs). Another DPP-4 inhibitor, vildagliptin, 
was approved in Europe in 2008. Saxagliptin (Onglyza®; 
Bristol-Myers Squibb) is also a potent, selective DPP-4 
inhibitor specifically designed for extended inhibition of 
the DPP-4 enzyme causing increased endogenous GLP-1 
concentration, and is now approved by the FDA.
Pharmacology
In patients with type 2 diabetes mellitus, administration of 
saxagliptin inhibits DPP-4 enzyme activity for a 24-hour 
period. The mean time to maximum concentration (Tmax) fol-
lowing the 5 mg once daily dose is 2 hours for saxagliption 
and 4 hours for its active metabolite 5-hydroxy saxagliptin. 
The maximum concentration (Cmax) and area under the 
curve (AUC) values of saxagliptin and its active metabolite 
increase proportionally in the 2.5 to 400 mg dose range. The 
metabolism of saxagliptin is primarily by cytochrome P450 
3A4/5 (CYP3A4/5). Therefore, strong CYP3A4/5 inhibitors 
and inducers alter the pharmacokinetics of saxagliptin and 
its active metabolite. Saxagliptin is excreted by both renal 
and hepatic pathways. 75% of saxagliptin is eliminated in 
the urine and 22% in the feces. Following a single oral dose 
of 5 mg saxagliptin to healthy subjects, the mean plasma 
terminal half-life (t1/2) for saxagliptin and its active metabolite 
was 2.5 and 3.1 hours, respectively.12
Clinical studies
Recent American Association of Clinical Endocrinologists 
(AACE) treatment guidelines have included incretin-based 
therapies such as DPP-4 inhibitors.13 The DPP-4 inhibitors 
are suggested to be used in the early stage of type 2 diabe-
tes, with a main indication in combination with metformin 
in subjects with inadequate glycemic control when treated 
with metformin alone. DPP-4 inhibition may also be used in 
combination with sulfonylurea and TZDs. Sitagliptin was the 
first DPP-4 inhibitor to be approved in the United States. As 
monotherapy, sitagliptin 25 to 200 mg/day reduced HBA1c 
from baseline by −0.28% to −0.76% at 12 to 24 weeks.14,15 
As initial therapy, sitagliptin–metformin combination 
therapy worked better than either sitagliptin or metformin 
monotherapy with an HbA1c reduction of 1.9% compared 
with 0.6% to 0.7%, and 1.13% after 24 weeks. As adjuvant 
therapy, sitagliptin in combination with metformin,   glipizide, 
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or pioglitazone yielded an HbA1c reduction of 0.6% to 0.7% 
when compared with placebo. Sitagliptin is renally eliminated 
and so its dose should be adjusted in patients with renal insuf-
ficiency.14,15 Vildagliptin, another DPP-4 inhibitor approved 
for use in Europe and under regulatory review in the United 
States is effective as adjuvant therapy when administered 
to patients inadequately controlled with sulfonylurea, met-
formin, TZD, or insulin therapy with HbA1c reduction of 
0.6%, 0.9%, 1.0%, and 0.5%, respectively.16,17 In addition, 
vildagliptin and pioglitazone were equally effective as adju-
vant therapy for patients who were inadequately controlled 
on metformin, in which HbA1c reductions of 0.9 and 1.0% 
were noted, respectively.18 Vildagliptin and sitagliptin have 
now been examined in a large number of subjects and shown 
to be tolerable and safe, the overall prevalence of adverse 
events has been similar to that seen in placebo groups both 
in monotherapy and in combination therapy with metformin, 
sulfonylurea or TZDs.14–18
Saxagliptin was approved by the FDA in July 2009, and 
is indicated as an adjunct to diet and exercise to improve 
glycemic control in adults with type 2 diabetes mellitus.12
Saxagliptin clinical trials
Monotherapy trials
In the 24-week placebo-controlled trial 401 inadequately 
controlled type 2 diabetes patients (HbA1c 7% to 10%) were 
randomized to receive 2.5, 5 or 10 mg saxagliptin or placebo. 
Results showed significant improvements in HbA1c, FPG and 
post-prandial glucose (PPG) in patients treated with saxaglip-
tin compared to placebo. Saxagliptin demonstrated statistically 
significant decreases in adjusted mean HbA1c changes from 
baseline (mean, 7.9%) to week 24 (−0.43%, −0.46%, −0.54%) 
for saxagliptin 2.5, 5, and 10 mg, respectively, vs +0.19% 
for placebo (all P , 0.0001). Adjusted mean FPG was sig-
nificantly reduced from baseline (−15, −9, −17 mg/dL) for 
saxagliptin 2.5, 5, and 10 mg, respectively, vs +6 mg/dL for 
placebo (P = 0.0002, p = 0.0074, P , 0.0001, respectively). 
PPG-AUC was reduced for saxagliptin 2.5, 5, and 10 mg 
(−6868, −6896, −8084 mg × min/dL, respectively) vs placebo 
(−647 mg × min/dL) with statistical significance demonstrated 
for saxagliptin 5 mg (P = 0.0002) and 10 mg (P , 0.0001). 
Saxagliptin was not associated with weight gain.19
Combination trials
initial combination therapy with metformin  
and saxagliptin
In a phase 3 randomized, double-blind, placebo-  controlled 
clinical trial of 1306 treatment-naïve adult patients with 
type 2 diabetes were evaluated over a 24-week period. 
Saxagliptin was coadministered with metformin in patients 
with inadequate glycemic control (HbA1c 8% to 12%) on diet 
and exercise alone. Patients were randomized to one of 4 
treatment arms: saxagliptin 5 mg plus metformin 500 mg, 
saxagliptin 10 mg plus metformin 500 mg, saxagliptin 10 mg 
plus placebo, or metformin 500 mg plus placebo. In the 3 
treatment groups receiving metformin, the metformin dose 
was up-titrated weekly in 500 mg/day increments, as toler-
ated, to a maximum of 2000 mg/day based on FPG. Patients 
who failed to meet specific glycemic goals during the studies 
were treated with pioglitazone rescue as add-on therapy. 
Saxagliptin 5 mg as initial combination therapy with met-
formin provided statistically significant reduction in HbA1c 
vs metformin plus placebo (−2.5% vs −2.0%, P , 0.0001) at 
6 months. In this study, a higher percentage (60%) of patients 
on combination therapy reached their HbA1c goal compared 
to patients on metformin plus placebo (41%).20
Add-on studies
In the phase 3, 24-week, randomized, placebo-controlled, 
double-blind clinical trial, the safety and efficacy of saxa-
gliptin in combination with metformin was evaluated in 743 
adult patients with inadequately controlled type 2 diabetes 
on metformin alone. Saxagliptin 2.5 mg and 5 mg added to 
metformin reduced HbA1c by −0.6%, and –0.7%, respec-
tively (P , 0.0001 vs placebo plus metformin) at 6 months. 
Saxagliptin 5 mg plus metformin resulted in a FPG reduction 
of −22 mg/dL (P , 0.05 vs placebo plus metformin, n = 187, 
baseline FPG 179 mg/dL) and a PPG reduction of −58 mg/dL 
(P , 0.05 vs placebo plus metformin, n = 155, baseline PPG 
296 mg/dL) at 6 months.21
In another add-on trial, 768 inadequately controlled 
diabetic patients on submaximal dose of glyburide were 
randomized to receive either 2.5 or 5 mg of saxagliptin 
add-on to 7.5 mg glyburide or to placebo plus a 10 mg 
total daily dose of glyburide. Patients who failed to meet 
specific glycemic goals during the study were rescued with 
metformin treatment, added on to existing study medication. 
Compared to up-titrated glyburide, saxagliptin 5 mg plus 7.5 
mg   glyburide provided statistically significant reductions 
in HbA1c at 6 months (−0.6% vs +0.1%, P , 0.0001).22 An 
increase from baseline in body weight, of small magnitude 
and unclear clinical relevance, occurred in all treatment 
groups; however, weight gain was higher in the saxagliptin 
treatment groups. Improved glycemic control has been shown 
to promote weight gain in certain instances by decreasing 
glucosuria.22
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Saxagliptin was also evaluated as add-on therapy with 
a TZD in 565 adult type 2 diabetes patients inadequately 
controlled on TZD alone. Patients were randomized to 
2.5 or 5 mg of saxagliptin or placebo in addition to their cur-
rent dose of TZD. At 6 months, HbA1c reduction with saxa-
gliptin 2.5 mg plus TZD was −0.7% (P , 0.05 vs   placebo plus 
TZD) vs placebo plus TZD, and −0.9% with 5 mg   saxagliptin 
plus TZD vs placebo vs TZD (P , 0.0001).23
Safety and tolerability
The most common adverse reactions reported in .5% of 
  saxagliptin-treated patients and more commonly than in 
controls were upper respiratory tract infection (7.7%, 7.6%), 
headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and 
urinary tract infection (6.8%, 6.1%). Discontinuation of 
therapy due to adverse events occurred in 3.3% and 1.8% 
of patients receiving saxagliptin and placebo, respectively. 
There was a dose-related mean decrease in absolute lympho-
cyte count observed with saxagliptin. The clinical signifi-
cance of this decrease is unknown. Hypersensitivity-related 
events such as urticaria and facial edema in the pooled analy-
sis up to week 24 were reported in 1.5%, 1.5% and 0.4% of 
patients who received saxagliptin 2.5 mg, saxagliptin 5 mg, 
and placebo, respectively.19,20,21 Analysis of pooled data also 
showed no significant weight gain or effect on lipid profile 
compared to placebo.19–24
The overall incidence of adverse events in medication-
  naïve patients receiving saxagliptin 5 mg as initial combination 
with metformin compared with those receiving placebo plus 
metformin was 55% vs 59%, respectively.20 These adverse 
events included headache (7.5% vs 5.2% with metformin 
plus placebo) and nasopharyngitis (6.9% vs 4.0% with met-
formin plus placebo). When used as add-on combination 
therapy with a TZD, the incidence of peripheral edema for 
saxagliptin 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 
4.3%, respectively.23 The rates of peripheral edema for saxa-
gliptin 2.5 mg and 5 mg vs placebo were 3.6% and 2% vs 3% 
when given as monotherapy,19 2.1% and 2.1% vs 2.2% when 
given as add-on therapy to metformin,20 and 2.4% and 1.2% 
vs 2.2% when given as add-on therapy to glyburide.22 In the 
add-on to glyburide study, the incidence of reported hypo-
glycemia was higher in patients treated with saxagliptin 5 mg 
plus glyburide (14.6%) vs placebo plus uptitrated glyburide 
(10.1%).22   However, the incidence of confirmed hypoglycemia 
in this study was 0.8% for saxagliptin 5 mg plus glyburide and 
0.7% for placebo plus up-titrated glyburide.22 The incidence 
of reported hypoglycemia with saxagliptin 5 mg vs placebo 
as add-on therapy to a TZD was 2.7% vs 3.8%,23 and the 
incidence of reported hypoglycemia with saxagliptin given as 
monotherapy was 5.6% compared to 4.1% for placebo.19
Summary
Management of type 2 diabetes is difficult because none of 
the commonly prescribed oral therapies address the progres-
sive decline in beta-cell function. Incretin-based therapies are 
associated with positive effects on beta-cell function, making 
them a potentially beneficial therapeutic option early in the 
disease when patients with type 2 diabetes still maintain some 
degree of beta-cell function. Although there no head-to-head 
studies comparing the different DPP-4 inhibitors, sitaglip-
tin, vildagliptin and saxagliptin have shown about equal 
efficacy of 0.4% to 0.8% HbA1c reduction. Saxagliptin is a 
potent DPP-4 inhibitor, which increases endogenous incretin 
levels. GLP-1 decreases glucose level by increasing insulin 
secretion in a glucose-dependent manner and by decreas-
ing plasma glucagon concentrations. Thus saxagliptin may 
give adult type 2 patients the extra help they need in their 
struggle to gain glycemic control. In phase 3 clinical trials 
placebo-corrected HbA1c reductions with saxagliptin 5 mg 
were −0.8% when added to metformin, −0.7% when added to 
glyburide, −0.6% when added to a TZD and −0.6% as mono-
therapy at 6 months. The overall incidence of adverse events 
was similar between saxagliptin and placebo (72% vs 71%, 
respectively). Saxagliptin is weight and lipid neutral, offers 
once-daily dosing, and is now approved by the United States 
FDA for the treatment of adults with type 2 diabetes.
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